Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8481526 | BAUSCH AND LOMB | Fluoroquinolone carboxylic acid molecular crystals |
Jan, 2031
(6 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8937062 | BAUSCH AND LOMB | Compositions and methods for treating, reducing, ameliorating, or preventing infections caused by antibacterial drug-resistant bacteria |
Nov, 2029
(5 years from now) | |
US8604020 | BAUSCH AND LOMB | Fluoroquinolone carboxylic acid molecular crystals |
Mar, 2030
(5 years from now) | |
US8415342 | BAUSCH AND LOMB | Besifloxacin ophthalmic composition for the treatment or control of infection |
Nov, 2030
(6 years from now) |
Besivance is owned by Bausch And Lomb.
Besivance contains Besifloxacin Hydrochloride.
Besivance has a total of 4 drug patents out of which 0 drug patents have expired.
Besivance was authorised for market use on 28 May, 2009.
Besivance is available in suspension/drops;ophthalmic dosage forms.
Besivance can be used as method of treating ocular bacterial infections.
The generics of Besivance are possible to be released after 09 January, 2031.
Drugs and Companies using BESIFLOXACIN HYDROCHLORIDE ingredient
Market Authorisation Date: 28 May, 2009
Treatment: Method of treating ocular bacterial infections
Dosage: SUSPENSION/DROPS;OPHTHALMIC